Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drugs aid weight loss among type 2 diabetes patients

18.02.2005


Three commonly used drugs -- Prozac, Xenical and Meridia -- may help type 2 diabetes patients lose small amounts of weight, although long-term benefits are not clear, a new review of 22 studies suggests.



Prozac and Sarafem, known generically as fluoxetine, are most commonly prescribed as antidepressants. Xenical, the brand name for orlistat, blocks fat digestion in the intestines. Meridia, known generically as subtramine, is an appetite suppressant that works in the brain.

According to the systematic evidence review by Dr. Susan Norris of the U.S. Centers for Disease Control and Prevention and colleagues, patients taking fluoxetine had lost an average of 11 pounds (5.1 kilograms) 24 to 26 weeks after starting the therapy. Patients taking orlistat had lost an average of four and a half pounds (two kilograms) 12 to 57 weeks later, and those taking sibutramine had lost an average of 11 pounds 12 to 52 weeks later. “The magnitude of weight loss is modest, however, and the long-term health benefits remain unclear,” the review concludes.


Side effects of the therapies included oily bowel movements for those taking orlistat; sweating, tremors and drowsiness among fluoxetine users; and heart palpitations in some sibutramine patients.

Although the researchers acknowledge that long-term weight loss is “of paramount importance,” they say their review could help determine how weight loss drugs should fit into the overall picture of type 2 diabetes care. “For example, if weight loss can be demonstrated with drugs in the short term, pharmacotherapy may be combined with behavioral interventions for long-term weight control,” Norris says.

The review appears in the latest issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

Although a variety of other weight loss drugs exist, only 22 randomized controlled studies of fluoxetine, orlistat and sibutramine met the high standards set by the researchers for inclusion in the review.

Of the 22 studies reviewed, the drugs’ manufacturers paid for 18 of them and did not provide the reviewers with unpublished studies the companies had done on each of the included drugs, Norris says. Norris says there is only a small amount of data on other weight loss drugs and people with type 2 diabetes. For instance, the researchers did not find any good studies examining the effects of popular weight loss drugs like ephedra in diabetic patients.

Obesity has been closely linked with type 2 diabetes. In a 2000 study, 80 to 90 percent of people with type 2 diabetes are overweight. Obesity may also worsen problems associated with diabetes, including high blood sugar, high cholesterol and high blood pressure, say Norris and colleagues. Norris says people with diabetes who are also overweight may have a harder time losing weight than non-diabetics.

Insulin therapy itself might cause weight gain, Norris says. Keeping track of a complex series of treatments for diabetes, high cholesterol and high blood pressure “all complicate behavioral change aimed at weight reduction.”

Recommendations by the American Diabetes Association in 2002 say that weight loss drugs may be useful in treating obesity among type 2 diabetes patients, but also note that “these drugs work best in conjunction with lifestyle strategies” such as low fat diets and increased exercise.

Norris and colleagues say more research is needed to find out whether weight loss drugs work better when combined with diet and exercise changes.

“In general populations, drugs have been combined with various lifestyle interventions, but most [drug] trials include relatively weak lifestyle programs, perhaps in part to better reveal the medication effects,” Norris says.

1. Norris et al. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus (Review).The Cochrane Database of Systematic Reviews 2005, Issue 1

Susan Norris | EurekAlert!
Further information:
http://www.hbns.org

More articles from Studies and Analyses:

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

nachricht Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Rainbow colors reveal cell history: Uncovering β-cell heterogeneity

22.09.2017 | Life Sciences

Penn first in world to treat patient with new radiation technology

22.09.2017 | Medical Engineering

Calculating quietness

22.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>